Approval
Cosentyx FDA Approval for PMR
The FDA approved Cosentyx 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering. In the Phase III REPLENISH trial, sustained remission at week 52 was 40.5% with Cosentyx 150 mg versus 20.5% with placebo, following a 24-week steroid taper. Serious adverse events occurred in 15.9% and 14.2% of the respective groups; a fatal cryptococcal meningitis case occurred in a Cosentyx-treated patient.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.